Test Price
2,800 AED✅ Home Collection Available
KDR Gene Hemangioma Susceptibility Genetic Test in UAE | 2800 AED | DHA Compliant
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection. Available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Genetic Counseling & Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test analyzes the full coding region of the KDR (VEGFR2) gene to identify germline variants associated with familial capillary infantile hemangioma susceptibility. It provides definitive genetic risk stratification for infants and families, enabling early surveillance and personalized care planning.
| Feature | Our Test (KDR NGS) | Standard Single-Gene Sequencing |
|---|---|---|
| Precision | Full gene coverage, including deep intronic regions & CNVs | Limited to select exons only |
| Method | ISO 9001:2015 NGS (Illumina® NovaSeq) | Sanger sequencing |
| Turnaround | 3–4 Weeks | 6–8 Weeks |
Physician Insight & Safety Protocols
"This genetic test identifies inherited KDR mutations linked to familial infantile capillary hemangioma. A positive result helps guide early dermatological and pediatric follow-up, but it is not a cancer diagnosis and must always be correlated with clinical findings. Please discuss all results with a certified genetic counselor."
– Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication without prior consultation with your treating physician. This test is for genetic risk assessment only and does not replace clinical management or therapeutic intervention.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Not suitable as a stand-alone test for active hemangioma complications without pre-test genetic counseling. Requires signed informed consent and documented pedigree analysis.
- Emergency Red Flags: In infants with known familial hemangioma, sudden enlargement, ulceration, active bleeding, or respiratory distress (airway hemangioma) mandates immediate pediatric emergency evaluation.
- Do not use this test in place of clinical diagnosis or as an emergency triage tool.
Patient FAQ & Clinical Guidance
1. What is the KDR gene hemangioma susceptibility test?
This genetic test screens for KDR gene mutations that increase the risk of familial infantile capillary hemangioma. It uses high-coverage NGS to detect pathogenic variants, guiding early surveillance for at-risk infants. The test requires a blood or DNA sample, with results available in 3–4 weeks.
2. How is the sample collected and how long until results?
Our VIP home collection service draws a small blood sample or accepts a DNA FTA card, completed in minutes. Samples are transported under strict cold-chain ISO conditions to our central laboratory, with a standard turnaround of 3–4 weeks. Digital and telephonic result support is provided by our genetic counselors.
3. Is this test covered by insurance in the UAE?
Many UAE insurance plans now cover NGS-based genetic testing for familial hemangioma susceptibility, subject to pre-authorization. Our team verifies your policy directly via WhatsApp at +971 54 548 8731, providing a cost estimate and required ICD-10 codes before you proceed.
UAE Regulatory & Data Privacy Adherence
Fully compliant with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | KDR Gene Hemangioma Susceptibility Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or DNA FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina® NovaSeq |
| ICD-10-CM Code | Z15.89 (Genetic Susceptibility to Other Disease) / D18.00 (Hemangioma) |
| LOINC Code | 55233-1 (Gene targeted mutation identification by sequencing) |
| DHA Facility License & Lab Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians